Home Journals Articles Updates About
CN
image
收藏切换
Advances in progress of drug targeting mixed lineage kinase-like protein
收藏切换
Yi-ming LI1, 2, Nan WANG2, Ya-xi YANG3, Zhu-shuang BAI1, Chao CHEN2, 3, *, Bing ZHOU1, 2, 3, *
Acta Pharmaceutica Sinica | 2026, 61(8) : 2867 - 2878
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(8): 2867-2878
• Reviews •
Advances in progress of drug targeting mixed lineage kinase-like protein
Full
Yi-ming LI1, 2, Nan WANG2, Ya-xi YANG3, Zhu-shuang BAI1, Chao CHEN2, 3, *, Bing ZHOU1, 2, 3, *
Affiliations
  • 1School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China
  • 2Shandong Laboratory of Yantai Drug Discovery, Yantai 264117, China
  • 3China State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Published: 2026-08-12 doi: 10.16438/j.0513-4870.2025-1596
Outline
收藏切换

The mixed lineage kinase domain-like protein (MLKL) is a "pseudokinase" that not only functions as a key effector molecule in the necroptosis pathway but also participates in the regulation of other programmed cell death pathways, thereby playing a crucial role in modulating various physiological processes. Dysregulation of MLKL activity is closely associated with the initiation and progression of multiple diseases, rendering it a highly promising therapeutic target. However, drug discovery targeting MLKL is still in its early stages, with no candidates having advanced to clinical trials. Thus, further in-depth and systematic investigations are urgently needed. This review summarizes the structural features, biological functions, and current progress in drug development targeting MLKL.

programmed cell death  /  necroptosis  /  the mixed lineage kinase domain-like protein  /  inhibitor  /  degrader
李一鸣, 王楠, 杨亚玺, 白著双, 陈超, 周兵. 靶向混合谱系激酶样蛋白MLKL的药物研究进展. 药学学报, 2026 , 61 (8) : 2867 -2878 . DOI: 10.16438/j.0513-4870.2025-1596
Yi-ming LI, Nan WANG, Ya-xi YANG, Zhu-shuang BAI, Chao CHEN, Bing ZHOU. Advances in progress of drug targeting mixed lineage kinase-like protein[J]. Acta Pharmaceutica Sinica, 2026 , 61 (8) : 2867 -2878 . DOI: 10.16438/j.0513-4870.2025-1596
Appendix
Less
Year 2026 volume 61 Issue 8
312
152
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2025-1596
  • Receive Date：2025-12-31
  • Online Date：2026-09-21
  • Published：2026-08-12
Article Data
Affiliations
History
  • Received：2025-12-31
  • Revised：2026-03-20
Affiliations
    1School of Pharmacy, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China
    2Shandong Laboratory of Yantai Drug Discovery, Yantai 264117, China
    3China State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-1596
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House